Immunwork, Inc.
🇨🇳China
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes
Phase 1
Active, not recruiting
- Conditions
- Overweight and Obesity
- Interventions
- Drug: TE-8105 MAD Cohort 2Drug: TE-8105 SAD Cohort 1Drug: TE-8105 SAD Cohort 2Drug: TE-8105 SAD Cohort 3Drug: TE-8105 SAD Cohort 4Drug: TE-8105 SAD Cohort 5 (Adaptive cohort)Drug: TE-8105 MAD Cohort 1
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Immunwork, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT06471530
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A Phase 1 Study of TE-8214 Solution in Healthy Volunteers
Phase 1
Completed
- Conditions
- Acromegaly
- Interventions
- Drug: PlaceboDrug: TE-8214 - SAD
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Immunwork, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06372652
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
News
No news found